Accurate prediction tools to facilitate risk stratification and therapeutic strategies for breast cancer patients with bone metastasis (BCBM) are lacking. We constructed and validated a new nomogram prognostic model, named NCC-BCBM, for breast cancer patients with bone metastasis using a large BCBM cohort from the SEER database. Clinical information for 8655 patients diagnosed from 2011 to 2013 was collected to develop the model. The predictive accuracy and discriminative ability of the nomogram were evaluated by concordance index (C-index) and calibration curve. The model was further validated in an independent cohort of 4634 BCBM patient. The following clinical variables were enrolled in the final prognostic model: age, race, surgery, radiation therapy, chemotherapy, laterality, grade, molecular subtype, American Joint Committee on Cancer (AJCC T) stage, AJCC N stage and extra metastatic sites except bone. The C-index for the developed model in training cohort was 0.702 (95% CI, 0.696 to 0.709). The calibration curve for probability of 1-year, 3-year and 5-year survival showed good agreement between prediction by nomogram and direct observation. C-index that validated in an independent cohort was 0.748 (95% CI, 0.737 to 0.759). We developed and validated a nomogram prognostic model for BCBM patients and it resulted in good performance.